Online inquiry

IVTScrip™ mRNA-Anti-TNFRSF8, MDX-060(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ11101MR)

This product GTTS-WQ11101MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets TNFRSF8 gene. The antibody can be applied in Hodgkin's disease (HD), Anaplastic large cell lymphoma (ALCL) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001243.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 943
UniProt ID P28908
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNFRSF8, MDX-060(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ11101MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ11703MR IVTScrip™ mRNA-Anti-IL13, MILR1444A(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MILR1444A
GTTS-WQ15545MR IVTScrip™ mRNA-Anti-NGcGM3, UNII-52G405U1E5(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA UNII-52G405U1E5
GTTS-WQ15428MR IVTScrip™ mRNA-Anti-LAG3, TSR-033(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA TSR-033
GTTS-WQ12430MR IVTScrip™ mRNA-Anti-IFNG, NI-0501(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA NI-0501
GTTS-WQ3725MR IVTScrip™ mRNA-Anti-MSLN, BAY 94-9343(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BAY 94-9343
GTTS-WQ4182MR IVTScrip™ mRNA-Anti-LAG3, BI-754111(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA BI-754111
GTTS-WQ8673MR IVTScrip™ mRNA-Anti-CD38, HuMax-CD38(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA HuMax-CD38
GTTS-WQ11850MR IVTScrip™ mRNA-Anti-TIGIT, MK-7684(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MK-7684
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW